Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Multiple studies examine ideal biomarkers for Huntington's disease

While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be especially helpful to monitor changes during the time prior to diagnosis and appearance of overt symptomatology.

21 May 2013

Research findings may pave way to new treatment for Alzheimer's disease in humans

A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment.

14 May 2013

Mouse study shows leukemia halts accumulation of toxic proteins linked to Parkinson's disease

Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects.

10 May 2013

TRACK-HD study: A set of tests could help identify progression of Huntington's disease

Scientists have identified a set of tests that could help identify whether and how Huntington's disease is progressing in groups of people who are not yet showing symptoms.

9 May 2013

Study: Melatonin delays symptom onset, reduces mortality in mouse model of ALS

Melatonin injections delayed symptom onset and reduced mortality in a mouse model of the neurodegenerative condition amyotrophic lateral sclerosis, or Lou Gehrig's disease, according to a new study by researchers at the University of Pittsburgh School of Medicine.

25 Apr 2013

Investigational treatment for ALS passes early phase clinical trial for safety

An investigational treatment for an inherited form of Lou Gehrig's disease has passed an early phase clinical trial for safety, researchers at Washington University School of Medicine in St. Louis and Massachusetts General Hospital report.

24 Apr 2013

Animal models of Huntington's disease allow better insights into disease's genetics

Scientific progress in Huntington's disease (HD) relies upon the availability of appropriate animal models that enable insights into the disease's genetics and/or pathophysiology.

23 Apr 2013

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.

20 Apr 2013

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

RNAi-based therapeutics company Benitec Biopharma Limited today announced that the company's wholly owned US subsidiary, Tacere Therapeutics Inc., has submitted an application to the US National Institutes of Health's Recombinant DNA Advisory Committee.

18 Apr 2013

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of California, San Diego, Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections.

16 Apr 2013

Junk DNA plays important role in brain development

Specific DNA once dismissed as junk plays an important role in brain development and might be involved in several devastating neurological diseases, UC San Francisco scientists have found.

16 Apr 2013

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

The Massachusetts General Hospital Neurological Clinical Research Institute and Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for amyotrophic lateral sclerosis, received a Best Practices Award at the 2013 Bio-IT World Conference & Expo.

15 Apr 2013

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.

9 Apr 2013

Clinical trial signals new era in treatment of neurodegererative disorders

The initial clinical trial of a novel approach to treating amyotrophic lateral sclerosis - blocking production of a mutant protein that causes an inherited form of the progressive neurodegererative disease - may be a first step towards a new era in the treatment of such disorders.

4 Apr 2013

Johns Hopkins scientists identify role of central nervous system cell in development of ALS

Johns Hopkins scientists say they have evidence from animal studies that a type of central nervous system cell other than motor neurons plays a fundamental role in the development of amyotrophic lateral sclerosis, a fatal degenerative disease.

1 Apr 2013

Molecular biologist hopes to learn why degenerative disorder affects specific brain cells

Dr. Santosh D'Mello, professor of molecular and cell biology at the University of Texas at Dallas, has received a federal grant for research that may shed light on why and how specific brain cells are affected by Huntington's disease, a devastating, degenerative brain disorder.

27 Mar 2013

USF, Saneron receive patent for transplantation method using umbilical cord blood cells

Researchers at Saneron CCEL Therapeutics and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as Parkinson's disease, Huntington's disease, multiple sclerosis, Alzheimer's disease as well as brain and spinal cord injury.

7 Mar 2013

Researchers discover how LRRK2 mutations in familial Parkinson's damage brain cells

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how the most common genetic mutations in familial Parkinson's disease damage brain cells.

4 Mar 2013

DDR may help decrease cognitive and physical effects of multiple sclerosis

Studies have shown that the popular video game, Dance Dance Revolution (DDR), which requires players to coordinate their movements to the beat of music, may help improve balance and mobility in certain patient populations.

28 Feb 2013

MID1 complex binds with messenger RNA and controls synthesis of defective Huntingtin

Huntington's disease, also known as Huntington's chorea, is a hereditary brain disease causing movement disorders and dementia. In Germany, there are about 8,000 patients affected by Huntington's disease, with several hundred new cases arising every year. The disease usually manifests between the ages of 35 and 50.

27 Feb 2013

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Multiple studies examine ideal biomarkers for Huntington's disease

Research findings may pave way to new treatment for Alzheimer's disease in humans

Mouse study shows leukemia halts accumulation of toxic proteins linked to Parkinson's disease

TRACK-HD study: A set of tests could help identify progression of Huntington's disease

Study: Melatonin delays symptom onset, reduces mortality in mouse model of ALS

Investigational treatment for ALS passes early phase clinical trial for safety

Animal models of Huntington's disease allow better insights into disease's genetics

Ceregene announces top-line data from CERE-12 Phase 2b clinical study for Parkinson's disease

Tacere Therapeutics submits TT-034 clinical trial application to Recombinant DNA Advisory Committee

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

Junk DNA plays important role in brain development

NCRI, Prize4Life recognized with Bio-IT World's Best Practices Award for creating PRO-ACT platform

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Clinical trial signals new era in treatment of neurodegererative disorders

Johns Hopkins scientists identify role of central nervous system cell in development of ALS

Molecular biologist hopes to learn why degenerative disorder affects specific brain cells

USF, Saneron receive patent for transplantation method using umbilical cord blood cells

Researchers discover how LRRK2 mutations in familial Parkinson's damage brain cells

DDR may help decrease cognitive and physical effects of multiple sclerosis

MID1 complex binds with messenger RNA and controls synthesis of defective Huntingtin

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in